Ionis Pharmaceuticals
Presence
Ionis Pharmaceuticals is one of the...
Ionis Pharmaceuticals is a company listed under the stock ticker IONS (US).
Executives
View the org chart displaying its 23 main executives
Most searched biographies at Ionis Pharmaceuticals
- Brett Monia, Chief Executive Officer and Director
- Joseph Loscalzo, Chairman of The Board
- Spencer Berthelsen, Director
Popular executive movements at Ionis Pharmaceuticals
- Kyle Jenne has joined the company as Executive Vice President and Chief Global Product Strategy Officer (posted on March 1 2024).
- Onaiza Cadoret-Manier, Executive Vice President, Chief Global Product Strategy and Operations Officer, has left the company (posted on March 1 2024).
- Michael Yang has joined the company as Director (posted on December 15 2023).
Create your alert
to follow the executive moves at Ionis Pharmaceuticals.
Biotechnology
Ionis Pharmaceuticals has 2,279 competitors including Eurofins (Luxembourg), Lonza (Switzerland) and Adaptive Phage Therapeutics (United States (USA)).
Popular M&A news in Biotechnology
- Metsera has just announced a $290 Million fundraising (posted on April 23 2024).
- Histogen has filed for bankruptcy protection (posted on April 19 2024).
- Bruker has announced the acquisition of NanoString Technologies (posted on April 18 2024).
Popular contacts in Biotechnology
News
Press releases by Ionis Pharmaceuticals
- Ionis reports third quarter 2023 financial results | Ionis Pharmaceuticals, Inc.
- Ionis to present at upcoming investor conferences | Ionis Pharmaceuticals, Inc.
- Ionis to present at upcoming investor conferences | Ionis Pharmaceuticals, Inc.
- Ionis reports second quarter 2023 financial results | Ionis Pharmaceuticals, Inc.
- Ionis completes enrollment in landmark Phase 3 CARDIO-TTRansform study in patients with TTR-mediated amyloid cardiomyopathy | Ionis Pharmaceuticals, Inc.
- Ionis enters collaboration to advance next generation program targeting Lp(a) for cardiovascular disease | Ionis Pharmaceuticals, Inc.
- Ionis to hold second quarter 2023 financial results webcast | Ionis Pharmaceuticals, Inc.
- Ionis expands eplontersen agreement with AstraZeneca to include exclusive rights in Latin America | Ionis Pharmaceuticals, Inc.
- Eplontersen continued to show improvement in ATTRv-PN through 85 weeks | Ionis Pharmaceuticals, Inc.
- Ionis to present at upcoming investor conference | Ionis Pharmaceuticals, Inc.
- View more press releases Close
Social media about Ionis Pharmaceuticals
- Ionis Pharmaceuticals on Wikipedia, Google News & Yahoo Finance
- Ionis Pharmaceuticals on LinkedIn, Twitter & YouTube
Get in Touch
Contact by email its executives including Brett Monia 
Call Ionis Pharmaceuticals at +1 760...
